EXCLUSIVE: Has Biotech Bottomed? NYSE Executive Floor Director Says Biogen And These 3 Stocks Look Poised To Outperform
EXCLUSIVE: Has Biotech Bottomed? NYSE Executive Floor Director Says Biogen And These 3 Stocks Look Poised To Outperform
Markets continue to trend lower amid rising inflation and Fed uncertainty, but one New York Stock Exchange floor director says the bottom may be in for a couple of beaten-down sectors.
What To Know: Jay Woods, chief market strategist at Drive Wealth and NYSE executive floor director, highlighted opportunities in biotech and health care stocks Wednesday on Benzinga's "Stock Market Movers."
"We're starting to see some strength there," Woods said.
Biogen Inc (NASDAQ:BIIB) was one of the stocks Woods focused on.
"We're seeing some technical progress," he said. "I'm starting to see some green shoots there."
Related Link: Here's How Much $100 Invested In Biogen 15 Years Ago Would Be Worth Today
When screening the sector for stocks with favorable technical setups showing relative strength, three names jumped out at Woods: Ionis Pharmaceuticals Inc (NASDAQ:IONS), Meridian Bioscience Inc (NASDAQ:VIVO) and Harmony Biosciences Holdings Inc (NASDAQ:HRMY).
"These are three little stocks in the sector that are starting to, you know, from a relative basis, act extremely well. And from a technical basis, you know, we're knocking on new highs and that's what I like to see," Woods said.
"If you are looking for stocks from a relative basis that are starting to outperform ... I think biotech and health care are some of the areas that you want to focus on."
Woods went on to name several health care names that are starting to look attractive.
Watch the full interview below to get the rest of Woods' stock picks:
Photo via Shutterstock.
Markets continue to trend lower amid rising inflation and Fed uncertainty, but one New York Stock Exchange floor director says the bottom may be in for a couple of beaten-down sectors.
在通脹上升和美聯儲不確定性的背景下，市場繼續走低，但紐約證交所的一個大廳董事表示，一些遭受重創的板塊可能已經觸底。
What To Know: Jay Woods, chief market strategist at Drive Wealth and NYSE executive floor director, highlighted opportunities in biotech and health care stocks Wednesday on Benzinga's "Stock Market Movers."
要知道的內容： 傑伊·伍茲，Drive Wealth首席市場策略師和紐約證交所高管大廳董事週三在Benzinga的《股市交易者》節目中強調了生物科技和醫療保健類股的機會。
"We're starting to see some strength there," Woods said.
“我們開始看到一些力量，”伍茲説。
Biogen Inc (NASDAQ:BIIB) was one of the stocks Woods focused on.
生物遺傳公司納斯達克(Sequoia Capital：BIIB)是伍茲關注的股票之一。
"We're seeing some technical progress," he said. "I'm starting to see some green shoots there."
“我們看到了一些技術上的進步，”他説。“我開始看到一些復甦的萌芽。”
Related Link: Here's How Much $100 Invested In Biogen 15 Years Ago Would Be Worth Today
相關鏈接：以下是15年前投資於生物遺傳公司的100美元今天的價值
When screening the sector for stocks with favorable technical setups showing relative strength, three names jumped out at Woods: Ionis Pharmaceuticals Inc (NASDAQ:IONS), Meridian Bioscience Inc (NASDAQ:VIVO) and Harmony Biosciences Holdings Inc (NASDAQ:HRMY).
在篩選具有相對強勢的有利技術設置的股票時，伍茲突然出現了三個名字：愛奧尼斯製藥公司 INC(納斯達克：Ions)，子午線生物科學公司(納斯達克：vivo)和和諧生物科學控股有限公司(納斯達克：HRMY)。
"These are three little stocks in the sector that are starting to, you know, from a relative basis, act extremely well. And from a technical basis, you know, we're knocking on new highs and that's what I like to see," Woods said.
伍茲表示：“這是該板塊中的三隻小股票，從相對基礎上看，它們的表現非常好。從技術基礎上看，我們正在創下新高，這是我希望看到的。”
"If you are looking for stocks from a relative basis that are starting to outperform ... I think biotech and health care are some of the areas that you want to focus on."
“如果你在相對的基礎上尋找開始跑贏大盤的股票……我認為生物科技和醫療保健是你想要關注的一些領域。”
Woods went on to name several health care names that are starting to look attractive.
伍茲接着列舉了幾個看起來開始有吸引力的醫療保健公司。
Watch the full interview below to get the rest of Woods' stock picks:
請看下面的完整採訪，瞭解伍茲的其他股票選擇：
Photo via Shutterstock.
照片來自Shutterstock。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧